Apparent gadolinium-based contrast enhancement was seen on precontrast-enhanced images on two breast magnetic resonance imaging (MRI) for a patient done 1 week apart. This was caused by ferumoxytol, which is used to treat some anemias. Such nongadolinium-based therapeutics exhibiting unintended MRI contrast-like properties preclude assessment of enhancement kinetics in breast MRI significantly limiting diagnostic interpretation. This case prompted a group discussion and subsequent modification to the patient breast MRI safety screening questionnaire at our institution.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.